Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8886479rdf:typepubmed:Citationlld:pubmed
pubmed-article:8886479lifeskim:mentionsumls-concept:C0034705lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0013030lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0001473lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0231174lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C1879725lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C1158360lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0597484lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:8886479lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:8886479pubmed:issue7lld:pubmed
pubmed-article:8886479pubmed:dateCreated1997-2-3lld:pubmed
pubmed-article:8886479pubmed:abstractTextDopamine decreases tubular sodium reabsorption in part by inhibition of Na+,K(+)-ATPase activity in renal proximal tubules. The signaling mechanism involved in dopamine-mediated inhibition of Na+,K(+)-ATPase is known to be defective in spontaneously hypertensive animals. The present study was designed to evaluate the role of phospholipase A2 (PLA2) and its metabolic pathway in dopamine-induced inhibition of Na+,K(+)-ATPase in renal proximal tubules from Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). Renal proximal tubular suspensions were prepared and Na+,K(+)-ATPase activity was measured as ouabain-sensitive adenosine triphosphate hydrolysis. Dopamine inhibited Na+,K(+)-ATPase activity in a concentration (1 nM-10 microM)-dependent manner in WKY rats while it failed to inhibit the enzyme activity in SHR. Dopamine (10 microM)-induced inhibition of Na+,K(+)-ATPase activity in WKY rats was significantly blocked by mepacrine (10 microM), a PLA2 inhibitor, suggesting the involvement of PLA2 in dopamine-mediated inhibition of Na+,K(+)-ATPase. Arachidonic acid (a product released by PLA2 action) inhibited Na+,K(+)-ATPase in a concentration-dependent (1-100 microM) manner in WKY rats while the inhibition in SHR was significantly attenuated (IC50: 7.5 and 80 microM in WKY rats and SHR, respectively). Furthermore, lower concentrations of arachidonic acid stimulated (30% at 1 microM) Na+,K(+)-ATPase activity in SHR. This suggests a defect in the metabolism of arachidonic acid in SHR. Proadifen (10 microM), an inhibitor of cytochrome P-450 monoxygenase (an arachidonic acid metabolizing enzyme) significantly blocked the inhibition produced by arachidonic acid in WKY rats and abolished the difference in arachidonic acid inhibition of Na+,K(+)-ATPase between WKY rats and SHR. These data suggest that PLA2 is involved in dopamine-induced inhibition of Na+,K(+)-ATPase and altered arachidonic acid metabolism may contribute to reduced dopaminergic inhibition of Na+,K(+)-ATPase activity in spontaneously hypertensive rats.lld:pubmed
pubmed-article:8886479pubmed:languageenglld:pubmed
pubmed-article:8886479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8886479pubmed:citationSubsetIMlld:pubmed
pubmed-article:8886479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8886479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8886479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8886479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8886479pubmed:statusMEDLINElld:pubmed
pubmed-article:8886479pubmed:monthOctlld:pubmed
pubmed-article:8886479pubmed:issn1064-1963lld:pubmed
pubmed-article:8886479pubmed:authorpubmed-author:LokhandwalaM...lld:pubmed
pubmed-article:8886479pubmed:authorpubmed-author:HussainTTlld:pubmed
pubmed-article:8886479pubmed:issnTypePrintlld:pubmed
pubmed-article:8886479pubmed:volume18lld:pubmed
pubmed-article:8886479pubmed:ownerNLMlld:pubmed
pubmed-article:8886479pubmed:authorsCompleteYlld:pubmed
pubmed-article:8886479pubmed:pagination963-74lld:pubmed
pubmed-article:8886479pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:meshHeadingpubmed-meshheading:8886479-...lld:pubmed
pubmed-article:8886479pubmed:year1996lld:pubmed
pubmed-article:8886479pubmed:articleTitleAltered arachidonic acid metabolism contributes to the failure of dopamine to inhibit Na+,K(+)-ATPase in kidney of spontaneously hypertensive rats.lld:pubmed
pubmed-article:8886479pubmed:affiliationInstitute for Cardiovascular Studies, College of Pharmacy, University of Houston, TX 77204-5511, USA.lld:pubmed
pubmed-article:8886479pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8886479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8886479lld:pubmed